The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment

HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodiu...

Descripción completa

Detalles Bibliográficos
Autores principales: Skinner-Adams, Tina S., Butterworth, Alice S., Porter, Kimberly A., D'Amico, Ronald, Sawe, Fred, Shaffer, Doug, Siika, Abraham, Hosseinipour, Mina C., Stringer, Elizabeth, Currier, Judith S., Chipato, Tsungai, Salata, Robert, Lockman, Shahin, Eron, Joseph J., Meshnick, Steven R., McCarthy, James S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317955/
https://www.ncbi.nlm.nih.gov/pubmed/22509297
http://dx.doi.org/10.1371/journal.pone.0034399
Descripción
Sumario:HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for ≥48 weeks; 73% also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this study population.

Ejemplares similares